Journal article

CCL17 blockade as a therapy for osteoarthritis pain and disease

Ming-Chin Lee, Reem Saleh, Adrian Achuthan, Andrew J Fleetwood, Irmgard Foerster, John A Hamilton, Andrew D Cook

ARTHRITIS RESEARCH & THERAPY | BMC | Published : 2018

Abstract

BACKGROUND: Granulocyte macrophage-colony stimulating factor (GM-CSF) has been implicated in the pathogenesis of a number of inflammatory diseases and in osteoarthritis (OA). We identified previously a new GM-CSF→Jmjd3→interferon regulatory factor 4 (IRF4)→chemokine (c-c motif) ligand 17 (CCL17) pathway, which is important for the development of inflammatory arthritis pain and disease. Tumour necrosis factor (TNF) can also be linked with this pathway. Here we investigated the involvement of the pathway in OA pain and disease development using the GM-CSF-dependent collagenase-induced OA (CiOA) model. METHODS: CiOA was induced in C57BL/6 wild-type (WT), Irf4 -/- , Ccl17 E/E , Ccr4 -/- , Tnf -/..

View full abstract

Grants

Awarded by Arthritis Australia


Awarded by National Health and Medical Research Council (NHMRC)


Awarded by Deutsche Forschungsgemeinschaft


Funding Acknowledgements

This work was supported by grants from Arthritis Australia (1757679) and the National Health and Medical Research Council (NHMRC) (1043147), and by a NMHRC Senior Principal Research Fellowship (JAH). IF was supported by the Deutsche Forschungsgemeinschaft IRTG 2168 (DFG).